Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma, Follicular 7Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia 2Thrombocytosis 1Signs and Symptoms, Digestive 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoid Malignancies 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

idelalisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoid Malignancies × idelalisib × Clear all
NCT02739360 2020-03-04

Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Gilead Sciences

Phase 4 Terminated
3 enrolled 5 charts

Lymphoid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡